EA
MDGL icon

Emerald Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Emerald Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6K Sell
70
-37,584
-100% -$19.3M ﹤0.01% 231
2026
Q1 		$19.7M Sell
37,654
-1,259
-3% -$601K 0.62% 69
2025
Q4 		$22.7M Sell
38,913
-11,824
-23% -$6.04M 0.7% 65
2025
Q3 		$23.3M Sell
50,737
-2,371
-4% -$885K 0.75% 57
2025
Q2 		$16.1M Buy
53,108
+5,199
+11% +$1.55M 0.59% 68
2025
Q1 		$15.9M Buy
47,909
+20,643
+76% +$6.78M 0.71% 57
2024
Q4 		$8.41M Buy
27,266
+1
+0% +$281 0.33% 91
2024
Q3 		$5.79M Sell
27,265
-69,499
-72% -$17.8M 0.22% 109
2024
Q2 		$27.1M Sell
96,764
-4,859
-5% -$1.16M 1.14% 28
2024
Q1 		$27.1M Buy
101,623
+53,901
+113% +$12.7M 1.09% 29
2023
Q4 		$11M Buy
47,722
+46,844
+5,335% +$8.2M 0.47% 85
2023
Q3 		$128K Sell
878
-60,605
-99% -$11.4M 0.01% 212
2023
Q2 		$14.2M Sell
61,483
-20,581
-25% -$5.57M 0.62% 75
2023
Q1 		$19.9M Buy
82,064
+69,076
+532% +$18.8M 0.95% 37
2022
Q4 		$3.77M Buy
+12,988
New +$1.27M 0.18% 110

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers's MDGL Position: Q2 2026 in Review

Emerald Advisers reduced its Madrigal Pharmaceuticals (MDGL) stake by 100% in Q2 2026, selling an estimated $19.3M and leaving 70 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #231.

Emerald Advisers first reported a position in MDGL in Q4 2022 and has held it in 15 quarters since. The position peaked at $27.1M in Q1 2024. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Emerald Advisers held 70 shares of Madrigal Pharmaceuticals worth $37.6K as of Q2 2026.
  • Emerald Advisers sold 37,584 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $19.3M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Emerald Advisers's portfolio in Q2 2026, its #231 holding.
  • Emerald Advisers first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Emerald Advisers's Madrigal Pharmaceuticals position peaked at $27.1M in Q1 2024.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.